First Header Logo Second Header Logo

Connection

Steven Kridel to Antineoplastic Agents

This is a "connection" page, showing publications Steven Kridel has written about Antineoplastic Agents.
Connection Strength

0.679
  1. Little JL, Kridel SJ. Fatty acid synthase activity in tumor cells. Subcell Biochem. 2008; 49:169-94.
    View in: PubMed
    Score: 0.208
  2. Kridel SJ, Lowther WT, Pemble CW. Fatty acid synthase inhibitors: new directions for oncology. Expert Opin Investig Drugs. 2007 Nov; 16(11):1817-29.
    View in: PubMed
    Score: 0.205
  3. Kridel SJ, Axelrod F, Rozenkrantz N, Smith JW. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res. 2004 Mar 15; 64(6):2070-5.
    View in: PubMed
    Score: 0.160
  4. Fels DR, Ye J, Segan AT, Kridel SJ, Spiotto M, Olson M, Koong AC, Koumenis C. Preferential cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of endoplasmic reticulum stress pathways. Cancer Res. 2008 Nov 15; 68(22):9323-30.
    View in: PubMed
    Score: 0.055
  5. Pemble CW, Johnson LC, Kridel SJ, Lowther WT. Crystal structure of the thioesterase domain of human fatty acid synthase inhibited by Orlistat. Nat Struct Mol Biol. 2007 Aug; 14(8):704-9.
    View in: PubMed
    Score: 0.050
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.